and Solutions IFF to welcome on everyone. XX% Frank Nourish driven double-digit third by $X.X overview in like of eight, would an I sales, basis, representing approximately growth growth you, comparable provide Thank currency-neutral billion quarter and our on divisions. Starting a year-over-year In QX, our Pharma generated slide primarily in performance.
running and is across quarter, businesses growth strong Pricing basis, a a and were were at growth our our Scent and which growth expected, factors And in that two-year most challenged. strong strong the year quarter. was of noted the ago volumes marginally volumes down volume to be comparison, average while X%. about as third Pharma It we parts on seen have contributor volume X% in should Nourish H&B
Protein our To demand. Solutions, provide to where seen in volume in response decline customer in nearly color, to some came we business, quarter of higher sluggish Nourish two-thirds end of have inventory destocking which consumer address the more is part levels the
adjusted negatively were direct we quarter, delivered and comparable EBITDA operating the faced Yet from and X% productivity pricing market of volumes reflected challenged In gains, through H&B, in IFF affected market significant strategic the third on weakening margin a result in basis. data. also Europe demand inflationary by pressures held markets. in across public Gross a our our growth US currency-neutral the was
We dollar business. to to we a In share impact amortization EBITDA saw the third to approximately impact adverse our sales, excluding headwind also $X.XX. an delivered per The earnings foreign on exchange. solid strong due an X% be adjusted X% on continued of quarter,
want Before Biosciences and we to rate the quarter recorded a are and that impacts The variations. Health drivers of $X.XX on cost primary exchange increases business. & impairment to business moving in lower non-cash I unfavorable to impairment charge the inflation due third related billion macroeconomic goodwill rates goodwill interest to our on, projections continued for of volume, adverse foreign related share
performance I all of provide third Now of we our currency-neutral moving achieved to segments growth sales sub-business will year-over-year of business slide business across the units. quarter, growth all across In nearly a sales segments. our the overview our brief broad-based XX% X, and by driven of
quarter saw strong strong with & Ingredients despite growth another pressure growth had business. Grain from in single-digit Nourish Processing and also performance our particularly Design. encouraging Food Flavors, Biosciences double-digit Health and
both industrial Ingredients increase with driven sales single-digits, Fragrance Scent pharma. the in an sales again Pharma Consumer Fine saw growth XX% our strength businesses. thanks Fragrance, by continued in to currency-neutral in and rebound continues Solutions continued impressive and high
to profitability slide for looking XX and the our quarter. Turning at
Comparable to fully due currency-neutral X% EBITDA actions adjusted million. EBITDA recover inflation. to adjusted quarter Third total grew operating totaled pricing the $XXX disciplined year-over-year
also productivity We operational efficiencies gains program, from headwinds. which helped volume achieved have offset productivity meaningful our and
last continue maintain targeted to will material offset profitability. taking quarter, appropriate to discussed clearly we are while signs As easing, seeing of inflation we inflation raw actions
Now growth discuss top-line segments. of another quarter our performance double-digit each underlying Flavors Nourish Food a to sustained on impacting business currency-neutral delivered growth was Ingredients, of in on Design slide the basis business. our quarter. XX, by sales XX% strong and I'd year-over-year and growth Nourish's like driven dynamics third the in
driven growth Food delivering mid and maintain strong by Nutrition growth & also Culture offerings. Health, in Biosciences currency-neutral Animal sales single-digit & comparable Enzymes, X% & Health Home our Personal Care performance in
X% respectively productivity offset currency-neutral of and EBITDA volumes. segments these for However, lower each we operating we decreases, discussed adjusted year-over-year in price X% earlier comparable as were increases our by gains and saw
with due Ingredients division single-digit growth volume strong and driven increases The high in performance growth Consumer by Fragrance sales productivity gains. quarter, once EBITDA to Fine growth, delivered Fragrance. and our in growth division again also mid-teen Scent X% saw price Fragrance in currency-neutral adjusted a operating Our currency-neutral growth this and X%
strong contributed leading the strong benefited the our an quarter growth impressive performance, currency-neutral XX% and by Solutions industrial. with growth EBITDA. very also in Solutions led XX% achieved Pharma double-digit Scent, pricing operating strong Similar sales, in growth to we gains pharma currency-neutral actions in from to volume, productivity adjusted and Pharma in
finishing X.X% result I Turning our generated Slide $XXX XX, negative nine $XXX now in approximately would from free CapEx of months cash $XXX first nine Through million. with our operations, million to The the we or months, leverage is position. through to was cover flow flow net cash sales. that like cash at a million and
and higher cash of slowing been has much levels by due free significantly combination a flow increases service and to volumes. to Our strategic impacted customer improved inventories inflation,
cash In addition, costs. included flow in deal our one-time numbers and are free integration-related
for and of implementing Much managing driven on will believe targets while are focus specific with each business we concert maintain parts result, the leveraging intense we of an new with S&OP improve in our all initiatives inventory unit, a improve processes our efficiency be customers. inventories flow levels to a series high tools this cash to As service down. across our which will business to of continuing by
addition, position. working cash taking to CapEx In reduce spend be we actions targeted to further capital and metrics improve our other improve will
to achieving continue make target. we towards Importantly, progress deleveraging our
As quarter recent finished Microbial Control EBITDA improved which totaled to Frank times debt $XXX mentioned with billion. gross equivalents cash we times, debt proceeds quarter while net was for supported divestiture. to X.X million, the We ratio third credit-adjusted our our from the by cash earlier, $XX.X and of X.X from
on our for the Turning Slide some consolidated want of the year. outlook our update expectations provide XX, remainder on I to to
foreign challenging face have exchange, and These business to since Our continues operational inflationary last persistent quarter. and increased pressures. conditions challenges other industry only with economic broader
by are environment. certainly across growth sales quarter, businesses of the each in especially We encouraged this achieved this consistent our
for further end-market our lower to adjusting decelerate expect exchange sales expectations are remain we due we foreign demand to significant QX, headwind. expect to as volume However, a and we
now also will year In we of comparable billion sales full and present between $XX.X full are factors, adjusted $XX.X growth factors operating and year adjusting to sales currency-neutral XX%. and expect light These of these X% billion our EBITDA. challenges guidance to
we as though discipline $X.X and at guidance billion, we volumes. end offset results strong are this and bottom reconfirming operating our EBITDA to headwinds of to $X.X persistent billion We be maintain of anticipate to cost accelerate productivity softer the range adjusted
into in the the cautious. us macroeconomic Looking a XXXX, next particularly low-volume result, And in be year. as growth half we current environment, of anticipate we first will makes a environment that
easing, and raw pricing energy In materials raw do require anticipate addition, year-over-year while inflation see increases markets, material we will in continued which additional volatile some actions. we
continue will our strong and allocation we to resource a focus across As our and our refine on accelerating discipline result, cost business. examine productivity to
ensure remains We resilient. will support implement pricing surgically, business also continue actions to our to profitability our
currency-neutral sales planning reinvest growth price comparable on EBITDA strong sales to growth our comparable the are in business as more early we to XXXX, still drive in currency-neutral more by driven in growth. a and process, predominantly accelerate it's targeting while long-term And basis, we with profitable momentum modest be
forward will exchange be continue rates. as headwind, a to current Foreign we roll spot
spend at Day, Investor XXXX will on few time in weeks. We our more a
I'll it back Frank, now turn closing comments. to for